Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation

References

• El-Far M, El-Motwally Ael G, Hashem IA, Bakry N. Biochemical role of intravaginal sildenafil citrate as a novel antiabortive agent in unexplained recurrent spontaneous miscarriage: first clinical study of four case reports from Egypt. Clin Chem Lab Med 2009;47:1433–8
   PubMed Web of Science ®Google Scholar
• Hill JA. Immunotherapy for recurrent pregnancy loss: “standard of care or buyer beware”. J Soc Gynecol Investig 1997;4:267–73
   PubMedGoogle Scholar
• Hunt JS. Immunologically relevant cells in the uterus. Biol Reprod 1994;50:461–6
   PubMed Web of Science ®Google Scholar
• Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril 2002;78:1073–6
   PubMed Web of Science ®Google Scholar
• Takasaki A, Tamura H, Miwa I, et al. Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium. Fertil Steril 2010;93:1851–8
   PubMed Web of Science ®Google Scholar
• Sher G, Herbert C, Maassarani G, Jacobs MH. Assessment of the late proliferative phase endometrium by ultrasonography in patients undergoing in-vitro fertilization and embryo transfer (IVF/ET). Hum Reprod 1991;6:232–7
   PubMed Web of Science ®Google Scholar
• Gonen Y, Casper RF. Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertilization (IVF). J In Vitro Fert Embryo Transf 1990;7:146–52
   PubMedGoogle Scholar
• Weckstein LN, Jacobson A, Galen D, et al. Low-dose aspirin for oocyte donation recipients with a thin endometrium: prospective, randomized study. Fertil Steril 1997;68:927–30
   PubMed Web of Science ®Google Scholar
• Sher G, Dodge S, Maassarani G, et al. Management of suboptimal sonographic endometrial patterns in patients undergoing in-vitro fertilization and embryo transfer. Hum Reprod 1993;8:347–9
   PubMed Web of Science ®Google Scholar
• Amit A, Thaler I, Paz Y, Itskovitz-Eldor J. The effect of a nitric oxide donor on Doppler flow velocity waveforms in the uterine artery during the first trimester of pregnancy. Ultrasound Obstet Gynecol 1998;11:94–8
   PubMed Web of Science ®Google Scholar
• Cameron IT, Campbell S. Nitric oxide in the endometrium. Hum Reprod Update 1998;4:565–9
   PubMed Web of Science ®Google Scholar
• Jerzak M, Kniotek M, Mrozek J, et al. Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage. Fertil Steril 2008;90:1848–53
   PubMed Web of Science ®Google Scholar
• Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000;15:806–9
   PubMed Web of Science ®Google Scholar
• Villanueva-Garcia D, Mota-Rojas D, Hernandez-Gonzalez R, et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol 2007;27:255–9
   PubMedGoogle Scholar
• Zinger M, Liu JH, Thomas MA. Successful use of vaginal sildenafil citrate in two infertility patients with Asherman’s syndrome. J Womens Health (Larchmt) 2006;15:442–4
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Cignarelli M, Sabatelli S, et al. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1998;69:471–3
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Seidler L, Scharer E, Bouchard P. [Non-oral administration of progesterone: experiences and possibilities of the transvaginal route]. Praxis (Bern 1994) 1995;84:127–33
   PubMedGoogle Scholar
• Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485–90
   PubMed Web of Science ®Google Scholar
• Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073–9
   PubMed Web of Science ®Google Scholar
• Degim IT, Tugcu-Demiroz F, Tamer-Ilbasmis S, Acarturk F. Development of controlled release sildenafil formulations for vaginal administration. Drug Deliv 2008;15:259–65
   PubMed Web of Science ®Google Scholar
• Ghorab D, Refai H, Tag R. Preparation and evaluation of fenoterol hydrobromide suppositories. Drug Discov Ther 2011;5:311–18
   PubMedGoogle Scholar
• British Pharmacopoeia. London, England: British Pharmacopoeia Commission; 2011
   Google Scholar
• Kale VV, Trivedi RV, Wate SP, Bhusari KP. Development and evaluation of a suppository formulation containing Lactobacillus and its application in vaginal diseases. Ann N Y Acad Sci 2005;1056:359–65
   PubMed Web of Science ®Google Scholar
• Jansson T, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond) 2007;113:1–13
   PubMed Web of Science ®Google Scholar
• Reynolds LP, Borowicz PP, Caton JS, et al. Uteroplacental vascular development and placental function: an update. Int J Dev Biol 2010;54:355–66
   PubMed Web of Science ®Google Scholar
• Reynolds LP, Caton JS. Role of the pre- and post-natal environment in developmental programming of health and productivity. Mol Cell Endocrinol 2006;354:54–9
   Google Scholar
• Krause BJ, Hanson MA, Casanello P. Role of nitric oxide in placental vascular development and function. Placenta 2011;32:797–805
   PubMed Web of Science ®Google Scholar
• Myatt L. Placental adaptive responses and fetal programming. J Physiol 2006;572:25–30
   PubMed Web of Science ®Google Scholar
• Tain YL, Huang LT. Asymmetric dimethylarginine: clinical applications in pediatric medicine. J Formos Med Assoc 2011;110:70–7
   PubMed Web of Science ®Google Scholar
• Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009;60:448–60
   PubMed Web of Science ®Google Scholar
• Kristoffersen EK, Ulvestad E. Nitric oxide synthase in human placenta. Apmis 1994;102:509–13
   PubMed Web of Science ®Google Scholar
• Martin D, Conrad KP. Expression of endothelial nitric oxide synthase by extravillous trophoblast cells in the human placenta. Placenta 2000;21:23–31
   PubMed Web of Science ®Google Scholar
• Purcell TL, Buhimschi IA, Given R, et al. Inducible nitric oxide synthase is present in the rat placenta at the fetal-maternal interface and decreases prior to labour. Mol Hum Reprod 1997;3:485–91
   PubMed Web of Science ®Google Scholar
• Roe CM, Leitch IM, Boura AL, Smith R. Nitric oxide regulation of corticotropin-releasing hormone release from the human perfused placenta in vitro. J Clin Endocrinol Metab 1996;81:763–9
   PubMed Web of Science ®Google Scholar
• Abbott D, Comby P, Charuel C, et al. Preclinical safety profile of sildenafil. Int J Impot Res 2004;16:498–504
   PubMed Web of Science ®Google Scholar
• Alatas E, Yagci B. Safety data for sildenafil. Fertil Steril 2002;78:1352–3
   PubMed Web of Science ®Google Scholar
• Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005;90:2550–5
   PubMed Web of Science ®Google Scholar
• Boyce EG, Umland EM. Sildenafil citrate: a therapeutic update. Clin Ther 2001;23:2–23
   PubMed Web of Science ®Google Scholar
• Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C–12C
   PubMed Web of Science ®Google Scholar
• Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C–20C
   PubMed Web of Science ®Google Scholar
• Cicinelli E, De Ziegler D, Morgese S, et al. “First uterine pass effect” is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril 2004;81:1414–16
   PubMed Web of Science ®Google Scholar
• Ficicioglu C, Gurbuz B, Tasdemir S, et al. High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004;18:240–3
   PubMed Web of Science ®Google Scholar
• Einer-Jensen N, Cicinelli E, Galantino P, et al. Uterine first pass effect in postmenopausal women. Hum Reprod 2002;17:3060–4
   PubMed Web of Science ®Google Scholar
• Frattarelli JL, Miller BT, Scott RT Jr. Adjuvant therapy enhances endometrial receptivity in patients undergoing assisted reproduction. Reprod Biomed Online 2006;12:722–9
   PubMed Web of Science ®Google Scholar
• Takatori T, Yamamoto K, Yamaguchi T, et al. Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid. Biol Pharm Bull 2005;28:1480–4
   PubMed Web of Science ®Google Scholar
• Kosior A. Biopharmaceutical evaluation of the intrarectal use of mefenamic acid. III. Effect of solubilizers on the biological availability of mefenamic acid from witepsol H15. Acta Pol Pharm 1986;43:156–60
   PubMedGoogle Scholar
• Lasserre Y, Peneva B, Jacob M, Puech A. Kinetics of release from suppositories formulated with phenobarbital acid or sodium, and semi-synthetic glyceride (Witepsol H 15). I. Freshly prepared suppositories. Pharm Acta Helv 1984;59:77–9
   PubMedGoogle Scholar
• Lasserre Y, Peneva MB, Jacob M, et al. Kinetics of liberation from suppository bases of phenobarbital acid and sodium and a semi-synthetic glyceride (Witepsol H 15). II. Suppositories after storage. Pharm Acta Helv 1987;62:287–91
   PubMedGoogle Scholar
• Usayapant A, Iyer BR. The effect of 2-hydroxypropyl-beta-cyclodextrin on in vitro drug release of steroids from suppository bases. Drug Dev Ind Pharm 1999;25:387–90
   PubMed Web of Science ®Google Scholar
• Yong CS, Sah H, Jahng Y, et al. Physicochemical characterization of diclofenac sodium-loaded poloxamer gel as a rectal delivery system with fast absorption. Drug Dev Ind Pharm 2003;29:545–53
   PubMed Web of Science ®Google Scholar
• Azechi Y, Ishikawa K, Mizuno N, Takahashi K. Sustained release of diclofenac from polymer-containing suppository and the mechanism involved. Drug Dev Ind Pharm 2000;26:1177–83
   PubMed Web of Science ®Google Scholar
• Babar A, Bellete T, Plakogiannis FM. Ketoprofen suppository dosage forms: in vitro release and in vivo absorption studies in rabbits. Drug Dev Ind Pharm 1999;25:241–5
   PubMed Web of Science ®Google Scholar
• Ceschel GC, Maffei P, Lombardi Borgia S, et al. Development of a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm 2001;27:541–7
   PubMed Web of Science ®Google Scholar
• Alexander NJ, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril 2004;82:1–12
   PubMed Web of Science ®Google Scholar
• Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 2001;16:1809–13
   PubMed Web of Science ®Google Scholar
• Scott DC, Hollenbeck RG. Design and manufacture of a zero-order sustained-release pellet dosage form through nonuniform drug distribution in a diffusional matrix. Pharm Res 1991;8:156–61
   PubMed Web of Science ®Google Scholar
• Desai SJ, Singh P, Simonelli AP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci 1966;55:1230–4
   PubMed Web of Science ®Google Scholar
• Higuchi T. Mechanism of Sustained-Action Medication. Theoretical Analysis of Rate of Release of Solid Drugs Dispersed in Solid Matrices. J Pharm Sci 1963;52:1145–9
   PubMed Web of Science ®Google Scholar
• Dhiman M, Yedurkar P, Sawant KK. Formulation, characterization, and in vitro evaluation of bioadhesive gels containing 5-Fluorouracil. Pharm Dev Technol 2008;13:15–25
   PubMed Web of Science ®Google Scholar
• Gil EC, Colarte AI, Bataille B, et al. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm 2006;317:32–9
   PubMed Web of Science ®Google Scholar
• Nafee NA, Ismail FA, Boraie NA, Mortada LM. Mucoadhesive delivery systems. II. Formulation and in-vitro/in-vivo evaluation of buccal mucoadhesive tablets containing water-soluble drugs. Drug Dev Ind Pharm 2004;30:995–1004
   PubMed Web of Science ®Google Scholar
• Quadir MA, Chanda E, Haider SS, et al. Evaluation of ethylcellulose as matrices for controlled release drug delivery. Pak J Pharm Sci 2005;18:29–34
   PubMedGoogle Scholar
• Ray S, Maiti S, Sa B. Polyethyleneimine-treated xanthan beads for prolonged release of diltiazem: in vitro and in vivo evaluation. Arch Pharm Res 2010;33:575–83
   PubMed Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29:297–310
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000;28:392–7
   PubMed Web of Science ®Google Scholar
• Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001;51:239–48
   PubMed Web of Science ®Google Scholar
• Baloglu E, Senyigit ZA, Karavana SY, Bernkop-Schnurch A. Strategies to prolong the intravaginal residence time of drug delivery systems. J Pharm Pharm Sci 2009;12:312–36
   PubMed Web of Science ®Google Scholar
• Terrett NK, Bell AS, Brown D, Ellis P. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996;6:1819–24
   Web of Science ®Google Scholar
• Smith DA, Jones BC, Walker DK. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996;16:243–66
   PubMed Web of Science ®Google Scholar
• Bulletti C, De Ziegler D, Giacomucci E, et al. Vaginal drug delivery: the first uterine pass effect. Ann N Y Acad Sci 1997;828:285–90
   PubMed Web of Science ®Google Scholar
• De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen AS. The first uterine pass effect. Ann N Y Acad Sci 1997;828:291–9
   PubMed Web of Science ®Google Scholar
• de Ziegler D. Hormonal control of endometrial receptivity. Hum Reprod 1995;10:4–7
   PubMed Web of Science ®Google Scholar
• Reynolds LP, Caton JS, Redmer DA, et al. Evidence for altered placental blood flow and vascularity in compromised pregnancies. J Physiol 2006;572:51–8
   PubMed Web of Science ®Google Scholar